<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118479</url>
  </required_header>
  <id_info>
    <org_study_id>2009 - P - 001874</org_study_id>
    <nct_id>NCT03118479</nct_id>
  </id_info>
  <brief_title>Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)</brief_title>
  <official_title>Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are doing this research study to look at the relationship between
      testosterone (the main sex hormone in men) and insulin (the hormone that controls blood sugar
      levels) in men with Idiopathic Hypogonadotropic Hypogonadism (IHH).

      The investigators hypothesize that normalizing testosterone levels in men with IHH enhances
      insulin sensitivity, reduces visceral fat, increases lean body mass, and improves the lipid
      profile.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because the PI left the institution.
  </why_stopped>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Actual">September 1, 2010</completion_date>
  <primary_completion_date type="Actual">September 1, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glucose tolerance</measure>
    <time_frame>Change between baseline and 3 months</time_frame>
    <description>Response to 75 g glucose load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Change between baseline and 3 months</time_frame>
    <description>IV glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat</measure>
    <time_frame>Change between baseline and 3 months</time_frame>
    <description>Assessed by CT of abdomen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting energy expenditure</measure>
    <time_frame>Change between baseline and 3 months</time_frame>
    <description>Assessed by metabolic monitor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <condition>Kallmann Syndrome</condition>
  <arm_group>
    <arm_group_label>Androgen only addback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined sex steroid addback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole Pill</intervention_name>
    <description>10 mg of Anastrozole to be taken daily for 3 months.</description>
    <arm_group_label>Androgen only addback</arm_group_label>
    <other_name>Arimidex (anastrozole)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Androgel 7.5 g to be applied transdermally daily for 3 months.</description>
    <arm_group_label>Androgen only addback</arm_group_label>
    <arm_group_label>Combined sex steroid addback</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>One tablet to be taken daily for 3 months</description>
    <arm_group_label>Combined sex steroid addback</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of idiopathic hypogonadotropic hypogonadism or Kallmann Syndrome

          -  mean testosterone level less than 300 ng/dl

          -  stable weight for the previous 3 months (no weight change greater than or equal to 10
             lbs)

          -  normal serum TSH

          -  normal serum prolactin levels

        Exclusion Criteria:

          -  Type 2 diabetes mellitus

          -  history of diabetes in parents

          -  sleep apnea

          -  bleeding disorder

          -  seeking fertility

          -  2 or more cardiovascular risk factors: smoking, hypertension, diabetes, dyslipidemias,
             family history of cardiovascular disease before age 60.

          -  history of previous cardiovascular event: myocardial infarction, unstable angina,
             cerebro-vascular accident.

          -  illicit drug use/alcohol use (&gt;4 drinks per day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelly Pitteloud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Frances Hayes</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>IHH</keyword>
  <keyword>KS</keyword>
  <keyword>Idiopathic hypogonadotropic hypogonadism</keyword>
  <keyword>GnRH deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Kallmann Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

